Literature DB >> 9054458

Human p53 binds Holliday junctions strongly and facilitates their cleavage.

S Lee1, L Cavallo, J Griffith.   

Abstract

Holliday junctions in DNA are generated as a product of homologous recombination events. To test the hypothesis that human p53 may bind to Holliday junctions, synthetic junctions with four approximately 75-base pair (Hol75) or approximately 565-base pair (Hol565) arms were generated. As seen by electron microscopy, under conditions in which 50-61% of the Hol565 DNAs were bound by p53, 80-96% of the p53 was located specifically at the junction with, in the latter case, only 4% of the p53 visualized at the DNA ends or along the arms. Given the large number of potential binding sites, this represents very high specificity for the junctions. Gel retardation assays using the Hol75 DNA confirm these observations, and indicate that the tight junction complexes have a half-life of greater than 4 h. The binding of p53 to three-way junctions is severalfold less than to four-way junctions. Addition of p53 greatly increases the rate of resolution of the Hol75 DNA by T4 endonuclease VII and T7 endonuclease I, two enzymes known to cleave such junctions. This latter finding further confirms the interaction of p53 with Holliday junctions and suggests that p53 binding facilitates their resolution in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9054458     DOI: 10.1074/jbc.272.11.7532

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  An ATP/ADP-dependent molecular switch regulates the stability of p53-DNA complexes.

Authors:  A L Okorokov; J Milner
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

Review 2.  Manipulating the mammalian genome by homologous recombination.

Authors:  K M Vasquez; K Marburger; Z Intody; J H Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-17       Impact factor: 11.205

3.  Physical and functional interactions of the tumor suppressor protein p53 and DNA polymerase alpha-primase.

Authors:  Christian Melle; Heinz-Peter Nasheuer
Journal:  Nucleic Acids Res       Date:  2002-04-01       Impact factor: 16.971

4.  Interactions between p53, hMSH2-hMSH6 and HMG I(Y) on Holliday junctions and bulged bases.

Authors:  Deepa Subramanian; Jack D Griffith
Journal:  Nucleic Acids Res       Date:  2002-06-01       Impact factor: 16.971

5.  Role of tumor suppressor p53 domains in selective binding to supercoiled DNA.

Authors:  Marie Brázdová; Jan Palecek; Dmitry I Cherny; Sabina Billová; Miroslav Fojta; Petr Pecinka; Borivoj Vojtesek; Thomas M Jovin; Emil Palecek
Journal:  Nucleic Acids Res       Date:  2002-11-15       Impact factor: 16.971

6.  Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein.

Authors:  Kristine McKinney; Carol Prives
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

7.  DNA end joining becomes less efficient and more error-prone during cellular senescence.

Authors:  Andrei Seluanov; David Mittelman; Olivia M Pereira-Smith; John H Wilson; Vera Gorbunova
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-28       Impact factor: 11.205

8.  p53 differentially inhibits cell growth depending on the mechanism of telomere maintenance.

Authors:  Zaineb R Abdul Razak; Robert J Varkonyi; Michelle Kulp-McEliece; Corrado Caslini; Joseph R Testa; Maureen E Murphy; Dominique Broccoli
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

9.  Resolving Holliday junctions with Escherichia coli UvrD helicase.

Authors:  Annamarie S Carter; Kambiz Tahmaseb; Sarah A Compton; Steven W Matson
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

10.  DNA substrate dependence of p53-mediated regulation of double-strand break repair.

Authors:  Nuray Akyüz; Gisa S Boehden; Silke Süsse; Andreas Rimek; Ute Preuss; Karl-Heinz Scheidtmann; Lisa Wiesmüller
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.